Patents by Inventor Nicholas Peter Franks

Nicholas Peter Franks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9326996
    Abstract: The present invention relates to the use of xenon in the preparation of a medicament for preventing and/or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject. The present invention further relates to combinations of xenon and sevoflurane, and use thereof as preconditioning agents for administration prior to hypoxic-ischaemic injury.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: May 3, 2016
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Publication number: 20150216897
    Abstract: The present invention relates to the use of xenon in the preparation of a medicament for preventing and/or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject. The present invention further relates to combinations of xenon and sevoflurane, and use thereof as preconditioning agents for administration prior to hypoxic-ischaemic injury.
    Type: Application
    Filed: February 10, 2015
    Publication date: August 6, 2015
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Publication number: 20100316729
    Abstract: Noble gases, in particular xenon and/or helium, administered under hyperbaric conditions of less than 3 atm (0.3 MPa), are used to provide neuroprotection, in particular in patients having suffered an impact trauma to the head and/or spinal column.
    Type: Application
    Filed: April 9, 2008
    Publication date: December 16, 2010
    Applicant: AIR PRODUCTS AND CHEMICALS, INC.
    Inventors: Nicholas Peter Franks, Mervyn Maze, Juan Carlos Sacristan Martin
  • Publication number: 20090311340
    Abstract: The present invention relates to the use of xenon in the preparation of a medicament for preventing and/or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject. The present invention further relates to combinations of xenon and sevoflurane, and use thereof as preconditioning agents for administration prior to hypoxic-ischaemic injury.
    Type: Application
    Filed: August 19, 2005
    Publication date: December 17, 2009
    Applicant: PROTEXEON LIMITED
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Patent number: 7632872
    Abstract: In a first aspect, the present invention relates to the use of xenon in the preparation of a medicament for providing analgesia in a newborn subject and/or a fetal subject. In a second aspect, the invention relates to a method of providing analgesia in a newborn subject, the method comprising administering to the subject a therapeutically effective amount of xenon. In a third aspect, the invention relates to a method of providing analgesia in a fetal subject, the method comprising administering to the mother of the fetal subject a therapeutically effective amount of xenon for both the mother and fetal subject.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: December 15, 2009
    Assignee: Protexeon Limited
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Patent number: 7442383
    Abstract: The present invention relates to methods of controlling neurological deficits in patients who have undergone cardiopulmonary bypass (CPB) by administering xenon to said patients.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: October 28, 2008
    Assignee: Protexeon Limited
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Patent number: 7390508
    Abstract: The present invention relates to the use of xenon in the preparation of a medicament for the treatment of neonatal asphyxia in a neonatal subject, wherein said medicament is for use in combination with hypothermia.
    Type: Grant
    Filed: October 11, 2004
    Date of Patent: June 24, 2008
    Assignee: Protexeon Limited
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Patent number: 6653354
    Abstract: The present invention relates to the use of xenon as a neuroprotectant and/or as an inhibitor of synaptic plasticity. In a preferred aspect, the xenon acts as an NMDA antagonist. The present invention also provides a method of reducing the level of activation of the NMDA receptors in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon, wherein said reduction achieves neuroprotection and/or an inhibition of synaptic plasticity. A further embodiment of the invention provides a pharmaceutical composition for providing neuroprotection and/or inhibition of synaptic plasticity, together with a process for the preparation thereof.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: November 25, 2003
    Assignee: Protexeon Limited
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Patent number: 6562855
    Abstract: A pharmaceutical composition is described. The composition comprises a formulation. The formulation comprises an NMDA antagonist and an alpha-2 adrenergic agonist. In a preferred aspect, there is provided an improved anaesthetic comprising an NMDA antagonist and an alpha-2 adrenergic agonist.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: May 13, 2003
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Publication number: 20020068764
    Abstract: The present invention relates to the use of xenon as a neuroprotectant and/or as an inhibitor of synaptic plasticity. In a preferred aspect, the xenon acts as an NMDA antagonist. The present invention also provides a method of reducing the level of activation of the NMDA receptors in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon, wherein said reduction achieves neuroprotection and/or an inhibition of synaptic plasticity. A further embodiment of the invention provides a pharmaceutical composition for providing neuroprotection and/or inhibition of synaptic plasticity, together with a process for the preparation thereof.
    Type: Application
    Filed: June 14, 2001
    Publication date: June 6, 2002
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Patent number: 6274633
    Abstract: The present invention relates to the use of xenon as an NMDA antagonist. In particular, the invention relates to a method of treatment comprising modulating the activity of an NMDA receptor in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon. In a further aspect, the invention provides a process for the preparation of a pharmaceutical composition suitable for modulating the activity of an NMDA receptor.
    Type: Grant
    Filed: August 23, 1999
    Date of Patent: August 14, 2001
    Assignee: Imperial College of Science, Technology, and Medicine
    Inventors: Nicholas Peter Franks, Mervyn Maze